Peter Loftus on Muck Rack

Peter Loftus Verified

Wall Street Journal @WSJ reporter covering pharmaceutical industry. Contact me at 215-881-7127, peter.loftus@wsj.com.

WHO Says Ebola Vaccine Effective in African Trial

wsj.com — European researchers said Friday that an experimental Ebola vaccine tested in Guinea "might be effective" in protecting people from the deadly virus, but behind the scenes, questions have been raised over the way the study was conducted. The vaccine, from Merck & Co. and NewLink Genetics Corp.
Jul 31, 2015

WHO Says Ebola Vaccine Effective in African Trial; controversy lingers on.wsj.com/1Iu4dyG My story via @WSJ

Jul 31, 2015

WHO Says Ebola Vaccine Effective in African Trial; controversy over trial protocol on.wsj.com/1Iu4dyG My story with @Loftus on @WSJ

Jul 31, 2015

WHO says Ebola vaccine 100% effective; debate continues. My @WSJ story w @Loftus wsj.com/articles/who-s… Getty Images pic.twitter.com/Ggj1nZS5i8

Show 11 more tweets from Stefanie Ilgenfritz, Andrew Seaman and others...

Merck Earnings Hurt by Arthritis Drug Knockoffs

wsj.com — Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second quarter, hurt by currency changes and recent divestitures.
Jul 28, 2015

Merck earnings hurt by knockoffs of arthritis drug Remicade in Europe: on.wsj.com/1IoKAIg via @WSJ $MRK

Jul 28, 2015

Biosimilars are already starting to bite at Merck, where 2Q earnings were hurt by biosimilar Remicade. on.wsj.com/1IoKAIg by @loftus

Jul 28, 2015

RT @JeanneWhalen: Biosimilars are already starting to bite at Merck, where 2Q earnings were hurt by biosimilar Remicade. on.wsj.com/1IoKAIg by @loftus

Jul 29, 2015

Remicade knockoffs, priced 45% below branded drug, hurt Merck earnings on.wsj.com/1IoKAIg

Jul 29, 2015

RT @helenwsj: Remicade knockoffs, priced 45% below branded drug, hurt Merck earnings on.wsj.com/1IoKAIg

Lilly’s Alzheimer’s drug may slow patients’ decline, study shows

marketwatch.com — WASHINGTON-People with mild Alzheimer's disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial. The outcome may bolster the case among investors that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer's patients, despite prior studies with negative results.

Lilly’s Alzheimer’s Drug May Slow Patients’ Decline, Study Shows

wsj.com — Separate study shows experimental Biogen drug also holds promise WASHINGTON-People with mild Alzheimer's disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.
Jul 22, 2015

Lilly’s Alzheimer’s drug may slow patients’ decline, study suggests on.wsj.com/1Jxlw2Q via @WSJ $LLY $BIIB #AAIC2015

Jul 22, 2015

RT @Loftus: Lilly’s Alzheimer’s drug may slow patients’ decline, study suggests on.wsj.com/1Jxlw2Q via @WSJ $LLY $BIIB #AAIC2015

Jul 22, 2015

RT @ShirleyWang: Lilly’s Alzheimer’s drug may slow patients’ decline, study shows on.wsj.com/1Jxlw2Q via @WSJ

Jul 22, 2015

RT @Loftus: Lilly’s Alzheimer’s drug may slow patients’ decline, study suggests on.wsj.com/1Jxlw2Q via @WSJ $LLY $BIIB #AAIC2015

Show 3 more tweets from Stefanie Ilgenfritz, Peter Loftus and others...

Rising U.S. Drug Prices Are Focus of Research Grant

wsj.com — A Houston philanthropist couple plans to announce Tuesday that they are providing a $5.2 million grant to a Boston nonprofit, the Institute of Clinical and Economic Review, to expand the group's research evaluating whether new drugs are worth their price tags. ICER research has already made a mark: Some U.S.
Jul 21, 2015

More focus on whether drugs offer V for M. Rising U.S. drug prices are focus of research grant on.wsj.com/1Ml7irJ via @WSJ

Jul 21, 2015

Rising U.S. drug prices are focus of $5M research grant from Arnold Foundation: on.wsj.com/1Ml7irJ via @WSJ

Show 8 more tweets from Rob Weisman, Stefanie Ilgenfritz and others...

Alzheimer’s Drug Is a Big Bet for Lilly

wsj.com — Researchers will provide clues about whether Eli Lilly & Co.'s risky bet on an experimental drug for Alzheimer's disease ultimately pays off-for patients and for Lilly's bottom line. Scientists are scheduled to present results from a clinical trial of the drug, solanezumab, at the Alzheimer's Association International Conference in Washington.
Jul 19, 2015

Key test for #Alzheimers drug candidate solanezumab--and $LLY--when data in mild patients is released Wed on.wsj.com/1LtaZKo by @Loftus

Jul 19, 2015

Researchers will provide clues this week about whether Lilly’s bet on an Alzheimer’s drug pays off on.wsj.com/1LtaZKo via @WSJ $LLY

Jul 20, 2015

Big test for Eli Lilly as it is set to release results on its new Alzheimer’s drug: on.wsj.com/1MjYOkP

Jul 20, 2015

Researchers will provide clues about whether Lilly’s bet on an Alzheimer’s drug pays off on.wsj.com/1LtaZKo via @WSJ

Jul 20, 2015

New Alzheimer's data from Lilly this week will help show whether there's any fight left in amyloid hypothesis on.wsj.com/1LtaZKo @loftus

Roche Says Drug Meets Bladder Cancer Target

wsj.com — An experimental Roche Holding AG drug, designed to unleash the body's immune system to fight cancer, shrank tumors in patients with advanced bladder cancer in a new clinical trial, the drug maker said Monday. Roche's Genentech unit, which developed the drug, atezolizumab, said it plans to discuss the results with health authorities in an effort to bring it to market as soon as possible.

FDA Approves Novartis’s Heart Failure Drug

wsj.com — Novartis AG's Entresto drug has been approved by the U.S. Food and Drug Administration for the treatment of heart failure. The FDA's decision is based on a study that enrolled nearly 8,5000 patients. The study ended early when it showed that Entresto "significantly" reduced the risk of death when compared with a treatment called enalapril, according to the Swiss pharmaceutical company.
Jul 08, 2015

RT @TomBurtonWSJ: FDA approves possible transformative drug for millions of #heartfailure patients, Novartis's Entresto. My @WSJ story wsj.com/article_email/…

Jul 08, 2015

FDA approves possible transformative drug for millions of #heartfailure patients, Novartis's Entresto. My @WSJ story wsj.com/article_email/…

Jul 08, 2015

RT @TomBurtonWSJ: FDA approves possible transformative drug for millions of #heartfailure patients, Novartis's Entresto. My @WSJ story wsj.com/article_email/…

Jul 08, 2015

RT @TomBurtonWSJ: FDA approves possible transformative drug for millions of #heartfailure patients, Novartis's Entresto. My @WSJ story wsj.com/article_email/…

Show 3 more tweets from Dinesh C Sharma, Peter Loftus and others...

U.S. Asks Appeals Court to Rehear Ruling Over Rare ‘Double Eagle’ Coins

blogs.wsj.com — The U.S. government hasn't given up its multiyear fight to hang on to 10 rare gold coins that a federal appeals court recently ruled should be given back to the heirs of a Philadelphia coin dealer who obtained them decades ago under mysterious circumstances. The U.S.
Jul 02, 2015

Revisiting an interesting custody battle over 10 rare gold coins, Feds versus family of Philly coin dealer: on.wsj.com/1IRUYc2 via @WSJ

Drug and Medical-Device Makers Paid $6.49 Billion to Doctors, Hospitals in 2014

wsj.com — Disclosure of health-care company payments to doctors part of federal transparency initiative Drug and medical-device makers paid $6.49 billion to U.S. doctors and teaching hospitals during 2014, according to the federal government's first full-year accounting of the breadth of industry financial ties with medical providers.
Jun 30, 2015

Drug & medical-device companies paid $6.49 billion to U.S. doctors & hospitals in 2014, new federal data shows. on.wsj.com/1IKXXmJ

Jun 30, 2015

RT @JeanneWhalen: Drug & medical-device companies paid $6.49 billion to U.S. doctors & hospitals in 2014, new federal data shows. http://t.…

Jun 30, 2015

Drug, medical-device makers paid $6.49 billion to U.S. doctors and hospitals during 2014 on.wsj.com/1IKXXmJ via @WSJ #OpenPayments

Jun 30, 2015

More than twice estimated cost of the device tax: Drug, medical-device makers paid $6.49 billion to docs, hospitals on.wsj.com/1IKXXmJ

Jun 30, 2015

Drug & medical-device makers paid $6.49 BILLION to US doctors and hospitals in 2014. @Loftus: on.wsj.com/1IKXXmJ

Show 7 more tweets from Nate Raymond, Elizabeth Yuan and others...
More Articles →
Jul 29, 2015

RT @John_LaMattina: @adamjshay @JeffDSachs @eperlste Plus, it's expensive. The recent relatively small PFE Lipitor OTC study cost at least $25 million to run.

Jul 28, 2015

RT @jonathanrockoff: Prescription drug spending up 12.6 percent in 2014, the highest growth since 2002, according to @CMSGov go.cms.gov/1FKpTuz

Jul 28, 2015

Merck earnings hurt by knockoffs of arthritis drug Remicade in Europe: on.wsj.com/1IoKAIg via @WSJ $MRK



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.